Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

BOTHELL, WA and VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone. The manuscript was published in the September 20, 2010 issue of the journal.

"The survival analysis provides a strong suggestion of clinical benefit with a hazard ratio consistent with a 50% reduction in the rate of death favoring custirsen treatment," said Dr. Kim Chi, Principal Investigator and medical oncologist at BC Cancer Agency. "These data provide the foundation and rationale for the upcoming SYNERGY Phase 3 trial evaluating custirsen in approximately 800 men with metastatic CRPC."

The study investigators concluded custirsen in combination with docetaxel was well tolerated. Furthermore, they noted that adverse events associated with custirsen, including lymphopenia, rigors and fever have been reported with other antisense therapeutics.

Analysis of trial results also showed:

- The observed survival benefit was attributed to the custirsen treatment rather than duration of docetaxel treatment or administration of subsequent therapies; - Fewer patients discontinued study therapy because of disease progression when custirsen was given (18% in custirsen plus docetaxel arm versus 39% in docetaxel arm), resulting in a greater number of treatment cycles administered (median of 9 cycles in custirsen plus docetaxel arm versus 7 cycles in docetaxel arm); - Statistically significant declines in serum clus
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
(Date:6/1/2015)... and YONGIN, South Korea , June ... that Green Cross Biotherapeutics Inc. (GCBT) kicked off construction ... on the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million ... projects in Canada in the ... first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... CHICAGO and RARITAN, N.J. ... & Development, LLC (Janssen) announced data from the ... significant improvement in progression-free survival (PFS) with trabectedin ... with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously ... additional chemotherapy regimen. SAR3007 is the largest randomized ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... for Talent is opening up. Tens of millions of people ... join, or are already in, the workforce - bringing expectations, ... Those organizations that can inspire the passion and harness the ... their competitors. Here's why. , ,Until recently, workers of ...
... note: Janet Dillione is president of the health services ... largest medical technology companies. She has something in common with Donna ... - both recently were named among the Top 25 women in ... are some excerpts from a recent WTN interview with Dillione. ...
... Court has issued several rulings that have eroded the strength ... v. AT&T , the Supreme Court delivered another blow by ... law governs domestically but does not rule the world. , , ... Court addressed Section 271(f) of the patent code, which prohibits a ...
Cached Biology Technology:Media-savvy workers: New front in the War for Talent 2Media-savvy workers: New front in the War for Talent 3Media-savvy workers: New front in the War for Talent 4Media-savvy workers: New front in the War for Talent 5Siemens health services president calls IT benefits unassailable 2Siemens health services president calls IT benefits unassailable 3Siemens health services president calls IT benefits unassailable 4Siemens health services president calls IT benefits unassailable 5Supreme Court limits foreign reach of U.S. patents 2Supreme Court limits foreign reach of U.S. patents 3Supreme Court limits foreign reach of U.S. patents 4
(Date:6/1/2015)... 2015 According to a new ... by Technology (Touch-based & Touchless), Application (Consumer Electronics, Automotive, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... to reach $23.55 Billion by 2020, at a CAGR ... Browse 83 market data T ables and   ...
(Date:6/1/2015)... 2015 According to a ... by Application (Government, Military & Defense, Healthcare, Banking ... Security), Technology (Face Recognition, Fingerprint Recognition, Iris Recognition, ... and Others), Function (Contact and Non-Contact) & Geography ... Europe , APAC, Row) - Global Forecast ...
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... Jrgen Kjems and Morten Trillingsgaard Ven, Department of Molecular ... contribute to an article on microRNA-128 just published in ... was possible to control the amount of microRNA-128 in ... "If microRNA-128 is kept down in these neurons in ...
... Ariz. A group of researchers from Arizona State University ... in the study of human proteins that could open up ... work is being reported in this week,s Science ... G-protein-coupled receptors," the team reports that they have been successful ...
... New York have reported the successful transformation of vegetable ... a structuring agent. The findings portend the development of ... acids, which have been linked to coronary artery disease, ... College Professor of Chemistry George John, tested two sugar ...
Cached Biology News:New research provides insight into epilepsy 2ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3CCNY chemists use sugar-based gelators to solidify vegetable oils 2
... of your microarray data using Asuragens bioinformatics ... from consultation to extensive data analysis using ... our expertise in combination with the Gene ... microarray experiments., ,Normalization and basic statistical analysis ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ...
... (OSM) is a pleiotropic cytokine produced by ... cells. OSM inhibits the growth of some ... smooth muscle and Kaposis sarcoma cell proliferation, ... density lipoprotein receptor expression on hepatoma cells. ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
Biology Products: